Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …

Background Thrombotic complications are considered among the main extrapulmonary
manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of …

Background Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2
infection, several scientific societies have proposed to increase the dose of preventive …

Background Thrombosis may contribute to morbidity and mortality in Covid-19. We
hypothesized that therapeutic anticoagulation would improve outcomes in critically ill …

Abstract Background: COVID-19–related critical illness is associated with an increased risk
of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the …

Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

Background Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …

Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …

Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19
have reported conflicting results. Objectives We sought to determine the safety and …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …